目次

1. Introduction to Antibody Drug Conjugates
1.1 Overview
1.2 Historical Development of ADCs
1.3 Evolution of Antibody Drug Conjugates

2. Need of Antibody Drug Conjugates

3. Global Antibody Drug Conjugate Market Insight
3.1 Current Market Scenario (2019 -2023)
3.2 Future Market Opportunity Assessment 2029

4. Antibody Drug Conjugate Market Regional Analysis
4.1 US
4.2 China
4.3 South Korea
4.4 India
4.5 Australia
4.6 Europe
4.7 Canada
4.8 Japan
4.9 Taiwan

5. Global Cancer Antibody Drug Conjugate Market Trends by Indication
5.1 Breast Cancer
5.2 Lung Cancer
5.3 Lymphoma
5.4 Leukemia
5.5 Cervical Cancer
5.6 Urothelial Cancer
5.7 Gastric Cancer
5.8 Other Cancers

6. Approved Antibody Drug Conjugates - Availability, Dosage and Price Insight 2023
6.1 Mylotarg
6.2 Adcetris
6.3 Kadcyla
6.4 Besponsa
6.5 Lumoxiti
6.6 Polivy
6.7 Padcev
6.8 Enhertu
6.9 Trodelvy
6.10 Blenrep
6.11 Zynlonta
6.12 Tivdak
6.13 Elahere
6.14 Aidixi
6.15 Ujvira
6.16 Akalux

7. Approved Antibody Drug Conjugate Sales Insights (Global and Regional, Yearly and Quaterly, 2019 -2023)
7.1 Adcetris
7.2 Padcev
7.3 Tivdak
7.4 Polivy
7.5 Kadcyla
7.6 Besponsa
7.7 Enhertu
7.8 Trodelvy
7.9 Zynlonta
7.10 Elahere
7.11 Blenrep

8. Global Antibody Drug Conjugates Clinical Trials Insight 2023
8.1 By Phase
8.2 By Indication
8.3 By Company
8.4 By Patient Segment
8.5 By Country

9. Global Cancer Antibody Drug Conjugates Clinical Pipeline By Company, Indication and Phase
9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-II/III
9.7 Phase-III
9.8 Preregistration

10. Marketed Cancer Antibody Drug Conjugates Clinical Insight

11. Global Cancer an Antibody Drug Conjugates Market Dynamics
11.1 Favorable Parameters
11.2 Challenges for Antibody Drug conjugates Market

12. Competitive Landscape
12.1 AbbVie
12.2 ADC Therapeutics
12.3 AstraZeneca
12.4 Bayer
12.5 BiOneCure Therapeutics
12.6 Biosion
12.7 Bio-Thera Solutions
12.8 Boehringer Ingelheim
12.9 Daiichi Sankyo Company
12.10 Duality Biologics
12.11 Exelixis
12.12 Genmab
12.13 Hangzhou DAC Biotech
12.14 Heidelberg Pharma AG
12.15 Iksuda Therapeutics
12.16 ImmunoGen
12.17 LaNova Medicines Limited
12.18 LegoChem Biosciences
12.19 Lepu Biopharma
12.20 Mersana Therapeutics
12.21 Molecular Templates
12.22 Multitude Therapeutics
12.23 NanoValent Pharmaceuticals
12.24 NewBio Therapeutics
12.25 Orum Therapeutics
12.26 ProfoundBio
12.27 Radiopharm Theranostics
12.28 Seagen
12.29 Sorrento Therapeutics
12.30 Sutro Biopharma

List of Figures & Tables
Figure 1-1: Historical Development of Antibody Drug Conjugates
Figure 1-2: Approval History of Commercially Available Antibody Drug Conjugates
Figure 1-3: Classification of Antibody Drug Conjugates
Figure 2-1: Therapeutic Index - Antibody Drug Conjugate vs. Cytotoxic Drug
Figure 3-1: Global - Antibody Drug Conjugate Market (US$ Billion), 2019-2023*
Figure 3-2: Global - Sales of ADCs for Breast Cancer v/s other indications (%), 2022
Figure 3-3: Global - Antibody Drug Conjugate Market Forecast (US$ Billion), 2023 - 2029
Figure 4-1: Tubulis - P5 Conjugation Platform Antibody
Figure 4-2: US - Sales of Cancer Antibody Drug Conjugates (US$ Million), 2023
Figure 4-3: US - Sales of Cancer Antibody Drug Conjugates (%), 2023
Figure 4-4: US - Sales of Cancer Antibody Drug Conjugates (US$ Million), 2022
Figure 4-5: US - Sales of Cancer Antibody Drug Conjugates (%), 2022
Figure 4-6: Pinot Bio - PINOT-ADCTM Platform Working Mechanism
Figure 4-7: Alteogen - NexMabandtrade; ADC technology
Figure 4-8: Canada - Cancer Incidence and Death, 2021
Figure 4-9: Adcetris - Canada Patents Numbers Approval and Expiration Dates
Figure 4-10: Padcev - Canada Patents Approval and Expiration Dates
Figure 4-11: Polivy - Canada Patents Numbers Approval and Expiration Dates
Figure 4-12: Enhertu - Canada Patents Numbers Approval and Expiration Dates
Figure 4-13: Trodelvy - Canada Patents Numbers Approval and Expiration Dates
Figure 4-14: Japan - Cancer Incidence and Death, 2022
Figure 6-1: Mylotarg - FDA Approval, Withdrawal and Re-Approval Year
Figure 6-2: Mylotarg - Approval Year by Region
Figure 6-3: UK - Cost of Supply of Mylotarg 5 mg Intravenous Powder (GBP/US$), May’2023
Figure 6-4: Mylotarg - Cost of Supply of Vial for Injection by Region (US$), May’2023
Figure 6-5: Mylotarg - Number of Induction Cycle and Consolidation Cycle Required for Treatment of Newly Diagnosed De Novo CD33-positive AML
Figure 6-6: Mylotarg - Cost of Induction Cycle, Consolidation Cycles and Full Treatment Cost of Newly Diagnosed De Novo CD33-positive AML (US$), May’2023
Figure 6-7: Mylotarg - Recommended Number of Induction and Continuation Cycle for Treatment of Newly Diagnosed CD-33 Positive AML
Figure 6-8: Mylotarg - Length of Induction and Continuation Cycle for Treatment of Newly Diagnosed CD-33 positive AML (Days)
Figure 6-9: Mylotarg - Recommended Dose of Initial Dose and Continuation Dose for Treatment of Newly Diagnosed CD-33 positive AML (mg/m2)
Figure 6-10: Mylotarg - Cost of Induction Phase and Continuation Phase and Full Treatment Cost of CD-33 positive AML (US$), May’2023
Figure 6-11: Mylotarg - Cost of Single Dose and Full Treatment Cost of Relapsed and Refractory CD33 Positive AML, May’2023
Figure 6-12: US - Adcetris Orphan Drug Designation Approval Year by Indication
Figure 6-13: US - Adcetris FDA Approval Year by Indication
Figure 6-14: Adcetris - Approval Year by Region
Figure 6-15: Japan - Adcetris PMDA Approval Year by Indication
Figure 6-16: Adcetris - Patent Expiration by Region
Figure 6-17: Adcetris - Cost of Supply of Vial for Injection by Region (US$), May’2023
Figure 6-18: Adcetris - Duration of Single Treatment Cycle and Full Treatment of Stage III and IV Classical Hodgkin Lymphoma (Weeks)
Figure 6-19: Adcetris - Maximum Cost of Single Treatment Cycle and Full Treatment of Stage III and IV Classical Hodgkin Lymphoma (US$), May’2023
Figure 6-20: Adcetris - Duration of Single Treatment Cycle and Full Treatment of Classical Hodgkin Lymphoma (Weeks)
Figure 6-21: Adcetris - Maximum Cost of Single Treatment Cycle and Full Treatment of Classical Hodgkin Lymphoma (US$), May’2023
Figure 6-22: Adcetris - Cost of Single Treatment Cycle and Full Treatment of Previously Untreated Systemic ALCL or Other CD30 T-Cell Lymphomas (US$), May’2023
Figure 6-23: Adcetris - Duration of Single Treatment Cycle and Full Treatment of Relapsed Primary Cutaneous ALCL or CD30-Expressing MF (Weeks)
Figure 6-24: Adcetris - Maximum Cost of Single Treatment Cycle and Full Treatment of Relapsed Primary Cutaneous ALCL or CD30-Expressing MF (US$), May’2023
Figure 6-25: US - Kadcyla FDA Approval Year by Indication
Figure 6-26: Kadcyla - Approval Years by Region
Figure 6-27: US - Kadcyla FDA Approval and Patent Expiration Year
Figure 6-28: US - Price for Single Unit of Kadcyla 100 mg and 160 mg Intravenous Powder for Injection (US$), May’2023
Figure 6-29: UK - Price for Single Unit of Kadcyla 100 mg and 160 mg Intravenous Powder for Injection (GBP/US$), May’2023
Figure 6-30: Kadcyla - Duration of Single Treatment Cycle and Full Treatment of Early Stage HER2+ Breast Cancer (Weeks)
Figure 6-31: Kadcyla - Average Cost of Single Treatment Cycle for Early Stage HER2 Breast Cancer in Human with Average Weight (US$), May’2023
Figure 6-32: Kadcyla - Recommended Dose after 1st and 2nd Dose Reduction (mg/kg)
Figure 6-33: Besponsa - Approval Year by Region
Figure 6-34: UK - Cost of Supply of Besponsa 0.9 mg Intravenous Powder (GBP/US$), May’2023
Figure 6-35: Besponsa - Cost of Supply of Vial for Injection by Region (US$), May’2023
Figure 6-36: Besponsa - Duration of Initial Treatment Cycle and Subsequent Cycles (Days)
Figure 6-37: Besponsa - Recommended Dose for 1st, 8th and 15th Day of Initial Treatment Cycle (mg/m2)
Figure 6-38: Besponsa - Cost of Single Unit and Full Cost of Initial Treatment Cycle (US$), May’2023
Figure 6-39: Besponsa - Cost of Single Unit and Full Cost of Subsequent Treatment (US$), May’2023
Figure 6-40: Besponsa - Duration of Treatment of ALL - After and Without HSCT (Weeks)
Figure 6-41: Lumoxiti - Orphan Designation Years
Figure 6-42: Lumoxiti - Patent Expiry Years
Figure 6-43: Lumoxiti - Duration of Single Treatment Cycle and Full Treatment (Weeks)
Figure 6-44: Lumoxiti - Cost of Single Dose, Single Treatment Cycle and Full Treatment of Hairy Cell Leukemia (US$), May’2023
Figure 6-45: Polivy - Orphan Drug Designation Approval Year by Region
Figure 6-46: US - Polivy Orphan Drug Designation Approval and Exclusivity Year
Figure 6-47: Polivy - Approval Year by Region
Figure 6-48: US - Price for Single Unit of Polivy 30 mg and 140 mg Intravenous Powder for Injection (US$), May’2023
Figure 6-49: UK - Price for Single Unit of Polivy 30 mg and 140 mg Intravenous Powder for Injection (GBP/US$), May’2023
Figure 6-50: Polivy - Duration of Single Treatment Cycle and Full Treatment (Weeks)
Figure 6-51: Polivy - Cost of Single Dose, Single Treatment Cycle and Full Treatment of Hairy Cell Leukemia with 30 mg Powder (US$), May’2023
Figure 6-52: Polivy - Cost of Single Dose, Single Treatment Cycle and Full Treatment of Hairy Cell Leukemia with 140 mg Powder (US$), May’2023
Figure 6-53: Padcev - Approval Year by Region
Figure 6-54: US - Padcev FDA Approval and Patent Expiration Year
Figure 6-55: US - Price for Padcev 20 mg and 30 mg Intravenous Powder for Injection (US$), May’2023
Figure 6-56: UK - Price for Padcev 20 mg and 30 mg Intravenous Powder for Injection (GBP/US$), May’2023
Figure 6-57: Padcev - Average Cost of Single Dose and Single Treatment Cycle with 20 mg Powder (US$), May’2023
Figure 6-58: Padcev - Average Cost of Single Dose and Single Treatment Cycle with 30 mg Powder (US$), May’2023
Figure 6-59: Padcev - Recommended Minimum Dose and Dose after Reduction for Urothelial Cancer (mg/Kg)
Figure 6-60: Padcev - Recommended Maximum Dose and Dose after Reduction for Urothelial Cancer (mg)
Figure 6-61: Enhertu - FDA Orphan Drug Designation and Exclusivity Expiration Year
Figure 6-62: Enhertu - Approval Year by Region
Figure 6-63: US - Polivy FDA Approval Year by Indication
Figure 6-64: UK - Cost of Supply of Enhertu 100 mg Intravenous Powder (GBP/US$), May’2023
Figure 6-65: Besponsa - Cost of Supply of Vial for Injection by Region (US$), May’2023
Figure 6-66: Enhertu - Recommended Dose by Cancer Type (mg/Kg)
Figure 6-67: Enhertu - Average Cost of Single Treatment Cycle and Annual Treatment Cost (US$), May’2023
Figure 6-68: Enhertu - Recommended Dose and Dose after Reduction for Breast Cancer (mg/Kg)
Figure 6-69: Enhertu - Recommended Dose and Dose after Reduction for Gastric Cancer (mg/Kg)
Figure 6-70: US - Trodelvy FDA Approval by Indication
Figure 6-71: Trodelvy - Approval Year by Region
Figure 6-72: Trodelvy - Patent Expiration by Region
Figure 6-73: Trodelvy - Average Cost of Single Dose, Single Treatment Cycle and Annual Treatment Cost (US$), May’2023
Figure 6-74: Trodelvy - Recommended Dose and Dose after Reduction (mg/Kg)
Figure 6-75: Blenrep - FDA and EMA Orphan Drug Designations
Figure 6-76: Blenrep - FDA and EMA Approval
Figure 6-77: Blenrep - Cost of Supply of 100 mg Intravenous Powder in US, EU and UK (US$), May’2023
Figure 6-78: Blenrep - Average Cost of Single Treatment Cycle and Annual Treatment Cost (US$), May’2023
Figure 6-79: Blenrep - Recommended Dose and Dose after Reduction (mg/Kg)
Figure 6-80: Zynlonta - FDA and EMA Orphan Drug Designation Years
Figure 6-81: Zynlonta - FDA and EMA Approval Years
Figure 6-82: Zynlonta - Recommended Dose for Initial and Subsequent Cycles (mg/kg)
Figure 6-83: Zynlonta - Average Cost of Single Treatment Cycle and Annual Treatment Cost (US$), May’2023
Figure 6-84: Tivdak - Average Cost of Single Treatment Cycle and Annual Treatment Cost (US$), May’2023
Figure 6-85: Tivdak - Recommended Dose and Dose after Reduction (mg/Kg)
Figure 6-86: US - Price per Unit and Single Supply of Elahere 100 mg/20 mL Intravenous Solution (US$), May’2023
Figure 6-87: UK - Price for Single Unit of Elahere 100 mg/20 mL Intravenous Solution (GBP/US$), May’2023
Figure 6-88: Aidixi - China Approval Year and FDA Breakthrough Therapy Designation Year
Figure 6-89: India - Price for Single Unit of Ujvira 100 mg and 160 mg Intravenous Powder for Injection (INR/US$), May’2023
Figure 6-90: India - Price for Single Unit of Branded and Biosimilar Trastuzumab Emtansine 100 mg Powder for Injection (INR/US$), May’2023
Figure 6-91: Ujvira - Duration of Single Treatment Cycle and Full Treatment of Early Stage HER2+ Breast Cancer (Weeks)
Figure 6-92: Ujvira - Cost of Single Treatment Cycle with 100 mg and 160 mg Powder for Early Stage HER2+ Breast Cancer (INR/US$), May’2023
Figure 6-93: Ujvira - Recommended Dose After 1st and 2nd Dose Reduction (mg/m2)
Figure 6-94: Akalux - Sakigake Designation and PMDA Approval Year
Figure 7-1: Global - Adcetris Annual Sales (US$ Million), 2019-2023
Figure 7-2: Global - Adcetris Quarterly Sales (US$ Million), 2022
Figure 7-3: Global - Padcev Annual Sales (US$ Million), 2019-2023
Figure 7-4: Global - Padcev Quarterly Sales (US$ Million), 2022
Figure 7-5: Global - Tivdak Annual Sales (US$ Million), 2021-2023
Figure 7-6: Global - Tivdak Quarterly Sales (US$ Million), 2022
Figure 7-7: Global - Polivy Sales Values (US$ Million), 2019-2023
Figure 7-8: Regional - Polivy Sales (US$ Million), Q1’2023
Figure 7-9: Regional - Polivy Annual Sales (%), Q1’2023
Figure 7-10: Global - Polivy Quarterly Sales (US$ Million), 2022
Figure 7-11: Regional - Polivy Annual Sales (US$ Million), 2022
Figure 7-12: Regional - Polivy Annual Sales (%), 2022
Figure 7-13: US - Polivy Annual Sales (US$ Million), 2019-2023
Figure 7-14: EU - Polivy Annual Sales (US$ Million), 2020-2023
Figure 7-15: ROW - Polivy Annual Sales (US$ Million), 2020-2023
Figure 7-16: US - Polivy Quarterly Sales (US$ Million), 2022
Figure 7-17: Europe - Polivy Quarterly Sales (US$ Million), 2022
Figure 7-18: ROW - Polivy Quarterly Sales (US$ Million), 2022
Figure 7-19: Global - Kadcyla Annual Sales Value (US$ Million), 2019-2023
Figure 7-20: Regional - Kadcyla Sales (US$ Million), Q1’2023
Figure 7-21: Regional - Kadcyla Annual Sales (%), Q1’2023
Figure 7-22: Global - Kadcyla Quarterly Sales (US$ Million), 2022
Figure 7-23: Regional - Kadcyla Annual Sales (US$ Million), 2022
Figure 7-24: Regional - Kadcyla Annual Sales (%), 2022
Figure 7-25: US - Kadcyla Annual Sales (US$ Million), 2019-2023
Figure 7-26: Europe - Kadcyla Annual Sales (US$ Million), 2020-2023
Figure 7-27: ROW - Kadcyla Annual Sales (US$ Million), 2020-2023
Figure 7-28: US - Kadcyla Quarterly Sales (US$ Million), 2022
Figure 7-29: Europe - Kadcyla Quarterly Sales (US$ Million), 2022
Figure 7-30: ROW - Kadcyla Quarterly Sales (US$ Million), 2022
Figure 7-31: Global - Besponsa Annual Sales (US$ Million), 2020-2023
Figure 7-32: Besponsa - Annual Sales by Region (US$ Million), Q1’2023
Figure 7-33: Besponsa - Quarterly Sales by Region (%), Q1’2023
Figure 7-34: Global - Besponsa Quarterly Sales (US$ Million), 2022
Figure 7-35: Regional - Besponsa Annual Sales (US$ Million), 2022
Figure 7-36: Regional - Besponsa Annual Sales (%), 2022
Figure 7-37: US - Besponsa Quarterly Sales (US$ Million), 2022
Figure 7-38: US - Besponsa Annual Sales (US$ Million), 2020-2023
Figure 7-39: Europe - Besponsa Quarterly Sales (US$ Million), 2022
Figure 7-40: Europe - Besponsa Annual Sales (US$ Million), 2020-2023
Figure 7-41: ROW - Besponsa Quarterly Sales (US$ Million), 2022
Figure 7-42: ROW - Besponsa Annual Sales (US$ Million), 2020-2023
Figure 7-43: Global - Enhertu Annual Sales (US$ Million), 2020-2023
Figure 7-44: Global - Enhertu Quarterly Sales (US$ Million), 2022
Figure 7-45: US - Enhertu Annual Sales (US$ Million), 2020-2023
Figure 7-46: US - Enhertu Quarterly Sales (US$ Million), 2022
Figure 7-47: Europe - Enhertu Annual Sales (US$ Million), 2020-2023
Figure 7-48: Europe - Enhertu Quarterly Sales (US$ Million), 2022
Figure 7-49: Japan - Enhertu Annual Sales (US$ Million), 2020-2023
Figure 7-50: Japan - Enhertu Quarterly Sales (US$ Million), 2022
Figure 7-51: Global - Trodelvy Annual Sales (US$ Million), 2020-2023
Figure 7-52: Global - Trodelvy Quarterly Sales (US$ Million), 2022
Figure 7-53: Regional - Trodelvy Annual Sales (%), 2022
Figure 7-54: Regional - Trodelvy Annual Sales (%), 2022
Figure 7-55: US - Trodelvy Annual Sales (US$ Million), 2020-2023
Figure 7-56: US - Trodelvy Quarterly Sales (US$ Million), 2022
Figure 7-57: Europe - Trodelvy Annual Sales (US$ Million), 2021-2023
Figure 7-58: Europe - Trodelvy Quarterly Sales (US$ Million), 2022
Figure 7-59: ROW - Trodelvy Annual Sales (US$ Million), 2022-2023
Figure 7-60: ROW - Trodelvy Quarterly Sales (US$ Million), 2022
Figure 7-61: Global - Zynlonta Annual Sales (US$ Million), 2021-2023
Figure 7-62: Global - Zynlonta Quarterly Sales (US$ Million), 2022
Figure 7-63: Global - Elahere Annual Sales (US$ Million), 2022-2023
Figure 7-64: Global - Blenrep Annual Sales (Euro/US$ Million), 2020-2023
Figure 7-65: Regional - Blenrep Sales (Euro/US$ Million), Q1’2023
Figure 7-66: Regional - Blenrep Annual Sales (Euro/US$ Million), 2022
Figure 7-67: Regional - Blenrep Annual Sales (%), 2022
Figure 7-68: Global - Blenrep Quarterly Sales (Euro/US$ Million), 2022
Figure 7-69: US - Blenrep Annual Sales (Euro/US$ Million), 2020-2023
Figure 7-70: US - Blenrep Quarterly Sales (Euro/US$ Million), 2022
Figure 7-71: Europe - Blenrep Annual Sales (Euro/US$ Million), 2020-2023
Figure 7-72: Europe - Blenrep Quarterly Sales (Euro/US$ Million), 2022
Figure 8-1: Global - Antibody Drug Conjugate In Clinical Trials By Phase, 2023
Figure 8-2: Global- Antibody Drug Conjugate In Clinical Trials By Indication, 2023
Figure 8-3: Global - Antibody Drug Conjugate In Clinical Trials By Company, 2023
Figure 8-4: Global - Antibody Drug Conjugate In Clinical Trials By Patient Segment, 2023
Figure 8-5: Global Antibody Drug Conjugate In Clinical Pipeline By Country, 2023
Figure 11-1: Antibody Drug conjugates Market Drivers
Figure 11-2: Challenges for Antibody Drug conjugates Market
Table 3-1: Approved Cancer Antibody Drug Conjugates
Table 5-1: Breast Cancer - Candidates Under Clinical Development
Table 5-2: Lung Cancer - Some Candidates under Clinical development
Table 5-3: Lymphoma - Some Candidates under Clinical development
Table 5-4: Leukemia - Some Candidates under Clinical development
Table 5-5: Urothelial Cancer - Some Candidates under Clinical development
Table 5-6: Gastric Cancer - Some Candidates under Clinical development
Table 5-7: Recent FDA/EMA Designations to Investigational ADCs